The US agency that regulates drugs is called the Food and Drug Administration, or FDA.
Compounding means making a medicine to order.
What each name describes
The single ingredient
Cagrilintide
An altered, lab-made copy of amylin, a body signal linked to fullness.
- Studied on its own for weight control.
The combination
CagriSema
Cagrilintide combined with semaglutide (Ozempic, Wegovy).
- Combination-study results belong to the pair.
A different ingredient
Semaglutide
Copies a body signal from the gut, involved in appetite and blood sugar.
- Ozempic and Wegovy are different product names for medicines containing semaglutide.
- Their approved uses differ: Wegovy includes weight management, while Ozempic has uses for adults with type 2 diabetes.
- Ask which product and which form—shot or tablet—the offer names.
What the dated records say
Cagrilintide
Cagrilintide had no approved US product at the September 28, 2026 check.
- Federal law did not allow cagrilintide in pharmacy compounding. FDA guidance said this at the September 26, 2026 check.
- An official patient price did not exist on September 28, 2026.
CagriSema
CagriSema was under FDA review for adult weight management. It had no US approval at the September 28, 2026 check.
- Filing for the combination did not seek approval of cagrilintide alone.
- No official US price was available at the September 28, 2026 check.
Semaglutide
Semaglutide (Wegovy) had an FDA-approved weight-management product at the September 26, 2026 check.
- Approval does not settle whether a product fits a person’s health or their plan’s coverage.
- Ask about the exact product, benefits, cautions and full cost.